I take your above points. I can't' ignore how significant the results were. Patients in the same epicentre with same treatment everyone else is getting and all of a sudden 75% off ventilators within 10 days, with 83% survival.
You mentioned there could be some reasons for the trail results. I understand, in this case all patients were on ventilators and 83%???? Also, Silvi Itescu said, big pharmas like Gilead with Remdesivir and Hydroxychloroquine have failed to date.
At the moment, MSB is in front in the home turn and worth the risk.
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-522
-
- There are more pages in this discussion • 326 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.030(2.03%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.51 | $1.43 | $6.613M | 4.498M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2482 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 27045 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |